Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.40 |
| ▸ | BRD2 | P25440 | 2/20 | 0.40 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.40 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | FABP6 | P51161 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14034514 | 0.84 | BRD4 (0.57) | BRD4BRD2BRD3BRDTALDH1A1 | |
| SCHEMBL14007197 | 0.81 | BRD4 (0.43) | BRD4BRD2BRD3BRDTALDH1A1 | |
| SCHEMBL1617368 | 0.71 | BRD4 (0.70) | BRD4BRD2BRD3BRDTALDH1A1 | |
| SCHEMBL1257213 | 0.71 | BRD4 (0.54) | BRD4BRD2BRD3BRDTALDH1A1 | |
| SCHEMBL4249708 | 0.70 | KDM4E (0.56) | BRD4BRD2BRD3BRDTALDH1A1 | |
| SCHEMBL16672390 | 0.69 | BRD4 (0.40) | BRD4BRD2BRD3BRDTALDH1A1 | |
| SCHEMBL1257017 | 0.69 | BRD4 (0.46) | BRD4BRD2BRD3BRDTALDH1A1 | |
| SCHEMBL924127 | 0.69 | GAA (0.71) | BRD4BRD2BRD3BRDTALDH1A1 | |
| SCHEMBL14884675 | 0.68 | BRD4 (0.57) | BRD4BRD2BRD3BRDTALDH1A1 | |
| SCHEMBL4251833 | 0.67 | BRD4 (0.42) | BRD4BRD2BRD3BRDTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280904-A1 | N-Substituted Pyridinone or Pyrimidinone Compounds Useful as Soluble Epoxide Hydrolase Inhibitors | ELDRUP ANNE BETTINA | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280904-A1 | N-Substituted Pyridinone or Pyrimidinone Compounds Useful as Soluble Epoxide Hydrolase Inhibitors | EPHX1, EPHX2, DOHH | BRD4 2988/4885BRD2 3385/4885BRD3 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.